WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS
PRIALT is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue PRIALT therapy in the event of serious neurological or psychiatric signs or symptoms.
PRIALT contains ziconotide, a synthetic equivalent of a naturally occurring conopeptide found in the piscivorous marine snail, Conus magus.
PRIALT (ziconotide) solution, intrathecal infusion is indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine.
Published Studies Related to Prialt (Ziconotide)
A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. [2006.05]
Safety and efficacy data from a study of slow intrathecal (IT) ziconotide titration for the management of severe chronic pain are presented. Patients randomized to ziconotide (n = 112) or placebo (n = 108) started IT infusion at 0.1 microg/hour (2.4 microg/day), increasing gradually (0.05-0.1 microg/hour increments) over 3 weeks...
Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. [2004.01.07]
CONTEXT: Ziconotide (formerly SNX-111) selectively blocks N-type voltage-sensitive calcium channels and may be effective in patients with pain that is refractory to opioid therapy or those with intolerable opioid-related adverse effects. OBJECTIVE: To assess the safety and efficacy of intrathecal ziconotide in patients with pain that is refractory to conventional treatment... CONCLUSION: Intrathecal ziconotide provided clinically and statistically significant analgesia in patients with pain from cancer or AIDS.
Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. [2000.05]
BACKGROUND AND OBJECTIVES: Voltage-sensitive calcium channel conductance is essential for the nervous system to signal a painful event. However, intrathecal administration of L-type calcium channel blockers does not provide analgesia. The present investigation was designed to assess the safety and analgesic efficacy of ziconotide, a new N-type calcium channel blocker, when administered intrathecally to patients with acute postoperative pain... CONCLUSIONS: Ziconotide showed analgesic activity, as shown by decreased PCA morphine equivalent consumption and lower VASPI scores. Because of a favorable trend of decreased morphine consumption with an acceptable side-effect profile in the low-dose ziconotide group, 0.7 microg/h may be closer to the ideal dose than 7 microg/h. Large-scale studies are required to clarify this issue.
Trigeminal neuralgia relief with intrathecal ziconotide. [2011.05]
OBJECTIVE: We report a case of a 59-year-old female with severe TN who experienced satisfactory symptom relief from a single-shot trial of intrathecal ziconotide.
Ziconotide: A rapid detoxification protocol for the conversion from intrathecal morphine--the Raffaeli Detoxification Model. [2011.01]
OBJECTIVES: To assess the efficacy and the safety of our rapid detoxificationprotocol in preventing signs and symptoms of withdrawal and pain severity... CONCLUSIONS: The detoxification protocol was effective in preventing withdrawal signs without increasing pain severity, allowing to rapidly convert IT morphine to ziconotide monotherapy in patients who are refractory to morphine.
Clinical Trials Related to Prialt (Ziconotide)
Intrathecal Bolus Doses of Ziconotide [Completed]
Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy [Active, not recruiting]
This is a phase 4 study being conducted at the Ohio State University Department of Neurology
Multiple Sclerosis Research Program. The purposes of the study is to administer a single
shot of intrathecal (injection into the space surrounding the spinal cord via a lumbar
puncture or spinal tap) ziconotide as a test dose to patients who have chronic painful
myelopathy (pain from spinal cord damage) or painful peripheral neuropathy (pain from nerve
damage) that has not responded to other pain medicines. Study Hypothesis: We intend to
determine if a single shot trial (SST) of intrathecal (IT) ziconotide will temporarily
reduce pain in these patients. In the proposed study, patients will receive two injections,
one of which is the ziconotide and one which is a placebo. They will be blinded and not
know which order they receive the treatment versus placebo. The results of this clinical
trial will provide a focused examination of ziconotide efficacy and safety in patients with
painful neuropathies or myelopathies that have not been effectively treated with other pain
medications. Moreover, the use of a single shot trial (SST) IT injection in the outpatient
setting will provide evidence for application of this technique in outpatient neurological
clinical practice, thereby improving access to this specific patient population. Ziconotide
is currently FDA approved for this indication and route of administration. Therefore, a
study design that improves the feasibility of ziconotide trialing specifically in the
neurology clinic (that is, single shot administration) is being used in order to ensure its
broader use by neurologists who routinely care for neuropathy and myelopathy patients.
Information from this study will also inform future studies of predictors for long term
efficacy after pump placement.
Prialt (Ziconotide) In Severe Chronic Pain [Completed]
The purpose of this study is to understand the effects of intrathecal ziconotide (an
experimental pain medication) when the dose is slowly increased over a 3-week period in
patients with severe chronic pain. During the weaning phase, the study will also gather
information about switching from other intrathecal or IT medication (slowly pumped directly
into the space around the spine) to other systemic pain medication (by mouth or through the
skin using a patch). After being weaned off current IT medication, patients will be placed
on IT ziconotide or placebo (non-active substance) as well as being allowed a stable dose of
systemic pain medications.
Patients who complete this study may be eligible for long-term ziconotide therapy via
extension protocol ELN92045-352.
Patient Registry of Intrathecal Ziconotide Management(PRIZM) [Recruiting]
The objectives of this study are to evaluate the effectiveness, long-term safety,
tolerability, satisfaction with treatment, and health-related quality of life (HRQoL)
associated with Intrathecal PRIALT use for severe chronic pain of varying etiologies.
Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain. [Completed]
This is an open-label, long-term, multi-centre multi-national postmarketing observational
registry. The objective of this study is to monitor the long-term efficacy, safety,
tolerability and quality of life outcomes associated with Prialt and other analgesics
utilised in the intrathecal management of severe chronic pain.
Reports of Suspected Prialt (Ziconotide) Side Effects
Weight Decreased (5),
Burning Sensation (5),
Psychotic Disorder (5),
Abdominal Pain (4),
Confusional State (4),
Abortion Spontaneous (4),
Overdose (4), more >>
Page last updated: 2011-12-09